Deca 500
Deca-500 Dragon Pharma — Overview
Deca-500 Dragon Pharma delivers Nandrolone Decanoate at 500 mg/ml — the highest-concentration single-ester nandrolone in the Dragon Pharma lineup. The active compound is identical to Deca-300; the distinction is purely practical: at 500 mg/ml, users running 500–600 mg/week of nandrolone need 1.0–1.2 ml per injection rather than 1.67–2.0 ml at 300 mg/ml. For high-dose protocols where injection volume is a real comfort consideration, Deca-500 is the more efficient option. The release profile, pharmacology, cycle structure, and side effect management are the same as any other nandrolone decanoate formulation.
Nandrolone Decanoate has a half-life of approximately 15 days — the slowest-clearing standard nandrolone ester — producing very stable, near-flat plasma levels with weekly or every-five-day injections once steady state is established at 3–4 weeks. Nandrolone has an anabolic-to-androgenic ratio of approximately 125:37 relative to testosterone, generating strong muscle anabolism with substantially lower androgenic burden in scalp, skin, and prostate than testosterone at comparable doses. Its clinically documented effects on joint tissue — collagen synthesis upregulation, increased proteoglycan content, improved synovial fluid — make it the standard choice for users managing joint pain alongside heavy training. A testosterone base is mandatory with any nandrolone formulation.
About the Compound: Nandrolone Decanoate at 500 mg/ml
Nandrolone is a 19-nor testosterone derivative — structurally identical to testosterone except for the removal of the carbon-19 methyl group. This modification alters how the compound interacts with 5-alpha reductase: rather than converting to DHT (as testosterone does), nandrolone converts to dihydronandrolone, a significantly weaker androgen at receptor sites in scalp, skin, and prostate. The compound is therefore highly anabolic in muscle tissue while producing substantially less androgenic burden in sensitive tissues than testosterone at equivalent anabolic doses.
The decanoate ester provides a 14–15 day half-life — the slowest-clearing standard nandrolone ester. Once-weekly injections maintain effective plasma levels, and blood levels between injections are among the most stable achievable with any injectable AAS. The trade-off is a 3–4 week onset period before steady-state concentrations are reached, and a corresponding 3-week clearance period after the last injection before PCT can begin effectively.
The 500 mg/ml concentration is the highest in the Dragon Pharma nandrolone range and exists specifically to reduce injection volume at higher doses. The pharmacokinetics, mechanism of action, and clinical behavior of the nandrolone released are identical regardless of the carrier concentration — 500 mg of nandrolone decanoate from Deca-500 (1 ml) behaves identically to 500 mg from Deca-300 (1.67 ml) once in systemic circulation. The concentration advantage is purely in delivery: less oil volume per injection, reduced injection site stress at high weekly doses, and fewer practical limitations on injection site rotation.
Nandrolone exerts anabolic effects through androgen receptor activation in skeletal muscle, nitrogen retention, IGF-1 upregulation, and satellite cell stimulation. It additionally upregulates type I and type III collagen synthesis and increases proteoglycan content in cartilage and synovial tissue — the connective tissue effect that distinguishes nandrolone from other injectable AAS in terms of joint support. Aromatization is approximately 20% of testosterone's rate; more clinically significant is nandrolone's progestogenic activity, which elevates prolactin and requires cabergoline (not AIs) for management.
What Deca-500 Does
- Lean mass accrual with lower water retention than equivalent testosterone doses — nandrolone's ~20% aromatization rate means less estrogen-driven water retention per milligram of anabolic activity than testosterone; gains on a nandrolone cycle are proportionally leaner and denser than on a testosterone-only cycle at equivalent total anabolic output; at the doses Deca-500 supports (400–600 mg/week in 0.8–1.2 ml), lean mass accumulation is progressive across the full 12–16 week cycle due to the flat, sustained nandrolone plasma levels the decanoate ester produces
- Joint support and connective tissue health — nandrolone stimulates type I and type III collagen synthesis and increases proteoglycan content in cartilage and synovial tissue, reducing joint pain and improving training capacity within 4–6 weeks of use; this effect is clinically documented in rheumatology literature and is the most reliably reported nandrolone benefit across both medical and performance contexts; it does not require high anabolic doses — 200–300 mg/week produces meaningful joint benefit; at the doses Deca-500 is typically used, joint support is a secondary benefit alongside the anabolic primary goal
- Nitrogen retention and sustained protein synthesis — nandrolone produces a strongly positive nitrogen balance at performance doses; the nitrogen retention effect relative to its androgenic activity is disproportionately large, reflecting the compound's high anabolic selectivity; combined with the flat blood levels from weekly decanoate dosing, this translates to continuous lean mass accrual throughout the cycle without the mid-cycle plateau that shorter-acting compounds can produce as receptor sensitivity adapts
- Erythropoiesis and recovery — nandrolone stimulates EPO production and red blood cell synthesis, improving oxygen-carrying capacity and inter-session recovery; the effect is additive with the testosterone base running alongside, and collectively produces the improved training frequency and volume capacity that users on combined test + nandrolone stacks report compared to either compound alone
- Lower per-injection volume than Deca-300 at equivalent doses — the defining practical advantage of Deca-500; at 500 mg/week, Deca-500 requires 1.0 ml per injection versus 1.67 ml for Deca-300; at 600 mg/week, the difference is 1.2 ml versus 2.0 ml; for users pinning weekly into the same rotation of sites, this reduction in oil volume meaningfully improves injection comfort and reduces site fatigue over a 12–16 week cycle
Who It's For
- Users running 500–600 mg/week nandrolone who want reduced injection volume — Deca-500's primary use case is high-dose nandrolone protocols where the volume difference versus Deca-300 is practically meaningful; at doses below 400 mg/week, the volume savings are modest (0.8 ml vs 1.33 ml) and the choice between concentrations is largely preference; above 500 mg/week, the 40–50% reduction in oil volume per injection is a real comfort and site-rotation benefit, particularly for users already injecting testosterone in the same weekly window
- Intermediate-to-advanced bulking cycles: test + high-dose nandrolone — Deca-500 fits advanced intermediate bulking stacks where the user has completed lower-dose nandrolone cycles and is scaling up; at 500–600 mg/week nandrolone alongside 400–500 mg/week testosterone, the anabolic combination is near the upper range of what evidence and practical experience support before the marginal benefit of additional dose decreases relative to side effect load; Deca-500 delivers this range in manageable injection volumes
- Users who have previously used Deca-300 and want higher-dose protocols with less oil — users already familiar with nandrolone's effects, side effect profile, and management protocol who are scaling to higher doses are the natural audience for Deca-500; the pharmacology is identical to what they have already used — only the delivery is more efficient; there is no new learning curve or side effect adjustment required for the concentration change itself
- Experienced users managing injection site rotation — users on multiple compounds simultaneously (e.g., testosterone + nandrolone + optional oral) must inject multiple products per week and manage site rotation carefully to prevent site fatigue, pip, and scar tissue accumulation; lower oil volume per injection meaningfully extends the sustainable rotation cycle, particularly on longer 16-week bulking phases
Combinations
Deca-500 requires an exogenous testosterone base. The following Dragon Pharma additions address specific cycle goals:
| Goal | Addition | Rationale |
|---|---|---|
| Testosterone base (mandatory) | Cypionat 250 Dragon Pharma | Nandrolone shuts down LH and FSH within weeks and does not provide sufficient androgenic tone to maintain libido, mood, or sexual function without exogenous testosterone; Cypionat 250 at 400–500 mg/week provides the test base; the long cypionate ester matches Deca-500's weekly injection schedule, keeping the total number of injection events per week to a minimum; for users who want both compounds pre-mixed at a 1:1 ratio, Deca 200 / Test E 200 combines nandrolone decanoate and testosterone enanthate in one vial |
| Oral kickstart | Dianabol 50 Dragon Pharma | The decanoate ester reaches effective steady-state in 3–4 weeks; dianabol at 30–50 mg/day for weeks 1–4 produces immediate mass and strength during the accumulation phase; this is especially relevant at the higher doses Deca-500 supports, where the user has a clear anabolic target that a 3–4 week ramp-up delays; AI management is important during the kickstart phase given dianabol's high aromatization rate stacked with the testosterone base |
| Lean mass without an oral kickstart | Anavar 50 Dragon Pharma | Oxandrolone at 50 mg/day in weeks 6–12 adds lean mass, strength, and vascularity without aromatization or additional progestogenic contribution to the stack; suitable for users at the second half of a 16-week cycle who want to sharpen the quality of mass accumulated in the first eight weeks; the combination of test + high-dose nandrolone + anavar produces leaner, more keepable gains than the test + nandrolone + dianabol protocol |
| Lower-concentration nandrolone for dose precision | Deca-300 Dragon Pharma | Some users prefer mixing Deca-500 and Deca-300 to hit specific non-round weekly doses that are awkward to measure in one concentration; for example, 350 mg/week is cleaner as 0.7 ml Deca-500 than as 1.17 ml Deca-300; alternatively, Deca-300 serves as a standalone choice for users at lower weekly doses where Deca-500's volume advantage is minimal |
| Dual-ester nandrolone for faster onset | Deca 200 / NPP 150 Dragon Pharma | For users who want to reduce the decanoate ester's 3–4 week buildup, adding Deca 200 / NPP 150 to the first 4–6 weeks of a Deca-500 cycle introduces an NPP component that produces measurable anabolic effect in weeks 1–2; once steady-state decanoate levels are established, the dual-ester blend can be discontinued and Deca-500 continued as the sole nandrolone source |
Side Effects & Management
The side effect profile of Deca-500 is identical to any nandrolone decanoate formulation — concentration does not change the compound's pharmacology. The two distinct mechanisms to manage are the progestogenic/prolactin pathway from nandrolone and the estrogenic pathway from the required testosterone base. Higher total weekly nandrolone doses increase the magnitude of prolactin elevation and require more attentive blood work monitoring.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Prolactin elevation and prolactin-related gynecomastia | Nandrolone binds progesterone receptors and elevates serum prolactin; at the 400–600 mg/week doses Deca-500 is used for, prolactin elevation is typically more significant than at lower nandrolone doses; prolactin-related gyno presents with nipple discharge and sensitivity — distinct from estrogen gyno (palpable glandular tissue, no discharge) — and does not respond to aromatase inhibitors; AIs only address the estrogen component, leaving prolactin unmanaged | Prolactin blood work before and every 6–8 weeks on cycle; Caberlin (Cabergoline) at 0.25–0.5 mg twice weekly suppresses prolactin directly via dopamine agonism; continue for 2–3 weeks into PCT as prolactin normalizes more slowly than sex hormones; aromatase inhibitors (Aromasin DP or Arimidex DP) run in parallel to manage estrogen from the testosterone base — two separate management tools for two separate pathways |
| Sexual dysfunction ("Deca Dick") | Nandrolone displaces testosterone at androgen receptors in sexual tissue but its 5-AR metabolite (dihydronandrolone) is far weaker than DHT, reducing androgen tone at sexual tissue receptors; elevated prolactin concurrently suppresses central libido; the combined effect worsens with higher nandrolone doses and with inadequate testosterone base; at 500–600 mg/week nandrolone, these effects are more pronounced than at lower doses and require proactive management rather than reactive intervention | Adequate testosterone base at minimum 350–400 mg/week; cabergoline for prolactin suppression; Proviron Dragon Pharma (mesterolone) at 25–50 mg/day specifically addresses the DHT deficit at sexual tissue receptors and is strongly recommended alongside high-dose nandrolone protocols; Cialis DP Dragon Pharma for on-demand support |
| HPTA suppression | Nandrolone produces deep, rapid suppression of LH and FSH; at 500–600 mg/week, recovery without on-cycle HCG support is substantially slower than at lower doses; the decanoate ester adds a 3-week post-cycle clearance requirement before PCT SERMs are effective, extending the total suppression window considerably on 12–16 week cycles | HCG 5000 IU Dragon Pharma at 500 IU EOD or 1,000 IU twice weekly throughout the cycle; on-cycle HCG is especially important at the doses Deca-500 supports; discontinue when SERM PCT begins; PCT (Clomid + Nolvadex) starts 3 weeks after last injection |
| Water retention | The testosterone base is the primary driver of estrogen-driven water retention in the stack; nandrolone's ~20% aromatization rate contributes modestly; at the higher total compound load (test + high-dose nandrolone), water retention is manageable with AI use but requires active monitoring — blood pressure rises with both the estrogen contribution and EPO-driven hematocrit elevation | Aromatase inhibitor for the testosterone component — Aromasin Dragon Pharma at 12.5 mg EOD or Arimidex Dragon Pharma at 0.5 mg EOD; blood work (serum E2) every 6–8 weeks; blood pressure monitoring; avoid over-suppression of estrogen, which worsens the joint environment and mood |
| Cardiovascular: HDL suppression, hematocrit | Both nandrolone and testosterone suppress HDL; at the combined doses of a high-dose nandrolone + testosterone cycle the lipid impact is meaningful across a 12–16 week cycle; EPO stimulation raises hematocrit, increasing blood viscosity and blood pressure; the combined cardiovascular load at higher doses is greater than at standard doses and warrants baseline and mid-cycle panels | Lipid panel and hematocrit at baseline and mid-cycle; omega-3 supplementation (3–4 g/day EPA+DHA); cardiovascular training throughout the cycle; for persistent HDL suppression, Rosulip (Rosuvastatin) or Atorlip (Atorvastatin); blood pressure management if hematocrit rises above 50% |
PCT
PCT timing for Deca-500 follows the same rule as any nandrolone decanoate formulation: wait 3 weeks after the last injection before starting SERM therapy. The decanoate ester's ~15-day half-life keeps nandrolone at suppressive levels for approximately 3 weeks post-injection, and beginning PCT during this window produces poor recovery. At the 400–600 mg/week doses typical for Deca-500, the depth of suppression makes on-cycle HCG particularly important for shortening recovery time. Blood work at 4–6 weeks post-PCT (total testosterone, LH, FSH, prolactin) confirms full recovery.
| Phase | Products | Protocol |
|---|---|---|
| On cycle — HCG (strongly recommended) | HCG 5000 IU Dragon Pharma | 500 IU EOD or 1,000 IU twice weekly throughout the cycle; at the higher nandrolone doses Deca-500 supports, on-cycle HCG shifts from recommended to strongly recommended — Leydig cell atrophy from extended deep suppression substantially extends recovery time without it; discontinue when SERM PCT begins |
| On cycle — prolactin management | Caberlin (Cabergoline) | 0.25–0.5 mg twice weekly throughout the cycle at doses above 400 mg/week nandrolone; prolactin elevation at these doses is more consistent than at lower nandrolone doses; continue cabergoline for 2–3 weeks into PCT — prolactin clearance lags sex hormone clearance and early discontinuation risks rebound |
| Wait before PCT | — | Approximately 21 days (3 weeks) after the last injection; governed by the decanoate ester's clearance; SERM therapy started earlier competes with residual nandrolone suppression and produces incomplete HPT axis recovery |
| PCT weeks 1–2 | Clomid Dragon Pharma + Nolvadex Dragon Pharma | Clomid 50 mg/day + Nolvadex 40 mg/day; Clomid drives LH and FSH recovery at both hypothalamic and pituitary level; Nolvadex provides complementary LH stimulation and breast tissue protection; combined SERM therapy is appropriate after a high-dose nandrolone + testosterone cycle |
| PCT weeks 3–4 (extend if needed) | Clomid Dragon Pharma + Nolvadex Dragon Pharma | Clomid 25 mg/day + Nolvadex 20 mg/day; taper as LH and FSH re-establish; extend to 6 weeks for cycles of 16 weeks or if mid-PCT blood work shows testosterone below range — more common after high-dose nandrolone cycles than after standard-dose protocols |
References
| Source | Topic | Link |
|---|---|---|
| PubMed / Clinical Rheumatology | Nandrolone decanoate pharmacology — anabolic steroid properties, therapeutic use context, effects on calcium balance, muscle mass, bone-related outcomes, and clinical application in osteoporosis | Geusens, 1995 ↗ |
| PubMed / Metabolism | Anabolic steroids and collagen synthesis — anabolic steroid therapy and type III collagen synthesis, providing general connective-tissue metabolism context | Hassager et al., 1990 ↗ |
| PubMed / Journal of Pharmacology and Experimental Therapeutics | Nandrolone ester pharmacokinetics — effects of ester type, injection site, and injection volume on nandrolone pharmacokinetics and pharmacodynamics | Minto et al., 1997 ↗ |
| PubMed / J Clin Endocrinol Metab | Nandrolone decanoate pharmacokinetics — serum and urine nandrolone/metabolite profiles after intramuscular nandrolone decanoate dosing in healthy men | Bagchus et al., 2005 ↗ |
| NCBI Bookshelf / StatPearls | Hyperprolactinemia physiology — prolactin elevation, reproductive dysfunction, drug-induced causes, diagnostic evaluation, and dopamine agonist treatment context | StatPearls: Hyperprolactinemia ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — androgen receptor mechanism, testosterone biosynthesis, DHT conversion, estradiol aromatization, androgen therapy, and androgen misuse context | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
What is Deca 500 used for?
Deca 500 is used for muscle growth and joint support in bulking cycles; see Key Benefits. It suits bodybuilders—consult professionals for safe use.
What does Deca 500 do?
It enhances muscle mass, strength, and joint health via nandrolone; see Mechanism of Action. It delivers robust gains—monitor with labs.
How long does Deca 500 stay in your system?
With a 6-7 day half-life, it's detectable for 12-18 months; see Mechanism of Action. Plan PCT accordingly—consult professionals.
How to use Deca 500?
Inject 300-600 mg/week, split weekly; see How to Use. Use with diet and monitoring—consult for tailored plans.
Is Deca 500 dangerous?
It's safe with proper use and monitoring; see Side Effects. Risks are manageable with ancillaries—consult professionals for safety.
How long does it take to notice the effects of Deca 500?
Because it contains a long ester, Deca 500 typically produces gradual results. Users often report improvements in recovery, training performance, and muscle fullness after several weeks.
What are the main benefits of Deca 500?
Commonly reported benefits include increased muscle mass, enhanced strength, improved recovery, better training capacity, and support for long-term muscle development.
What makes Deca 500 different from other nandrolone products?
Deca 500 stands out because of its higher concentration, allowing more nandrolone decanoate to be delivered per milliliter while maintaining the long-acting characteristics associated with traditional Deca formulations.
Related Products
